Transplantation of Highly Purified CD34+Thy-l+ Hematopoietic Stem Cells in Patients with Metastatic Breast Cancer

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 3, 2000, Pages 262-271

  Negrin, Robert S ^a   Atkinson, Kerry ^b   Leemhuis, Tom ^b   Hanania, Elie ^b   Juttner, Christopher ^b   Tierney, Kathryn ^a   Hu, Wendy W ^a   Johnston, Laura J ^a   Shizuru, Judith A ^a   Stockerl Goldstein, Keith E ^a   Blume, Karl G ^a   Weisswan, Irving L ^c   Bower, Stephanie ^d   Baynes, Roy ^d   Dansey, Roger ^d   Karanes, Chatchada ^d   Peters, William ^d   Klein, Jared ^d  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Stem cells; Transplantation; Tumor purging

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BREAST TUMOR; CLINICAL TRIAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; STEM CELL MOBILIZATION;

ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARMUSTINE; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0033643040     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70008-5     Document Type: Article

References (45)

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
2. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.
3. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993;11:1132-1143.
4. Antman KH, Rowlings PA, Vaughan WP. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America [see comments]. J Clin Oncol. 1997;15:1870-1879.
5. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial [see comments]. J Clin Oncol. 1995;13:2483.
6. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med. 2000;342:1069-1076.
7. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993;341:85-86.
8. Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 1994;83:3068-3076.
9. Yeager AM, Kaizer H, Santos GW, et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycy-clophosphamide. N Engl J Med. 1986;315:141-147.
10. Negrin RS, Kusnierz-Glaz CR, Still BJ, et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood. 1995;85:3334-3341.
11. Sheridan WP, Beglet CG, Juttner CA, et al. Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet. 1992;339:640-644.
12. Schmitz N, Linch DC, Dreger P, et al. Randomized trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347:353-357.
13. Shpall EJ, Champlin R, Glaspy JA, et al. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant. 1998;4:84-92.
14. Glaspy JA, Shpall EJ, LeMaistre CF, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood. 1997;90:2939-2951.
15. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85:588-596.
16. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol. 1984;133:157-165.
17. Strauss LC, Rowley SD, La Russa VF, Sharkis SJ, Stuart RK, Civin CI. Antigenic analysis of hematopoiesis. V. Characterization of My-10 antigen expression by normal lymphohematopoietic progenitor cells. Exp Hematol. 1986;14:878-886.
18. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic stem cells. Science. 1988; 241:58-62.
19. Smith LG, Weissman IL, Heimfeld S. Clonal analysis of hematopoietic stem-cell differentiation in vivo. Proc Natl Acad Sci USA. 1991;88:2788-2792.
20. Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Miura Y, Suda T. Enrichment and characterization of murine hematopoietic stem cells that express c-kit molecule. Blood. 1991;78:1706-1712.
21. Uchida N, Combs J, Chen S, Zanjani E, Hoffman R, Tsukamoto A. Primitive human hematopoietic cells displaying differential efflux of the Rhodamine 123 dye have distinct biological activities. Blood. 1996;88:1297-1305.
22. Bertoncello I, Hodgson GS, Bradley TR. Multiparameter analysis of transplantable hemopoietic stem cells: I. The separation and enrichment of stem cells homing to marrow and spleen on the basis ofrhodamine-123 fluorescence. Exp Hematol. 1985; 13:999-1006.
23. Spangrude GJ, Johnson GR. Resting and activated subsets of mouse multipotent hematopoietic stem cells. Proc Natl Acad Sci U S A. 1990;87:7433-7437.
24. Uchida N, Tsukamoto A, He D, Priera AM, Scollay R, Weissman IL. High doses of purified stem cells cause early hematopoietic recovery in syngeneic and allogeneic hosts. J Clin Invest. 1998;101:961-966.
25. Uchida N, Aguila HL, Fleming WH, Jerabek L, Weissman IL. Rapid and sustained hematopoietic recovery in lethally irradiated mice transplanted with purified Thy-1.1lo Lin-Sca-1+ hematopoietic stem cells. Blood. 1994;83:3758-3779.
26. Baum QM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA. 1992;89:2804-2808.
27. Craig W, Kay R, Cutler RL, Lansdorp PM. Expression of thy-1 on human hematopoietic progenitor cells. J Exp Med. 1993; 177:1331-1342.
28. Terstappen LW, Huang S, Safford M, Lansdorp PM, Loken MR. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38-progenitor cells. Blood. 1991;77:1218-1227.
29. Keating A, Powell J, Takahashi M, Singer JW. The generation of human long-term marrow cultures from marrow depleted of Ia (HLA-DR) positive cells. Blood. 1984;64:1159-1162.
30. Lu L, Walker D, Broxmeyer HE, Hoffman R, Hu W, Walker E. Characterization of adult human marrow hematopoietic progenitors highly enriched by two-color cell sorting with My10 and major histocompatibility class II monoclonal antibodies. J Immunol. 1987;139:1823-1829.
31. Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med. 1998;4:1038-1045.
32. Sutherland DR, Yeo EL, Stewart AK, et al. Identification of CD34+ subsets after glycoprotease selection: engraftment of CD34+Thy-1+Lin-stem cells in fetal sheep. Exp Hematol. 1996;24:795-806.
33. Murray L, Chen B, Galy A, et al. Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin-subpopulation from mobilized peripheral blood. Blood. 1995;85:368-376.
34. Stewart AK, Imrie K, Keating A, Anania S, Nayar R, Sutherland DR. Optimizing the CD34+ and CD34+Thy-1+ stem cell content of peripheral blood collections. Exp Hematol. 1995;23:1619-1627.
35. Ishizawa L, Hangoc G, Van de Ven C, et al. Immunomagnetic separation of CD34+ cells from human bone marrow, cord blood, and mobilized peripheral blood. J Hematother. 1993;2:333-338.
36. Sasaki DT, Tichenor EH, Lopez F, et al. Development of a clinically applicable high-speed flow cytometer for the isolation of transplantable human hematopoietic stem cells. J Hematother. 1995;4:503-514.
37. Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988;6:1368-1376.
38. Gazitt Y, Reading CC, Hoffman R, et al. Purified CD34+Lin-Thy+ stem cells do not contain clonal myeloma cells. Blood. 1995;86:381-389.
39. Tricot G, Gazitt Y, Leemhuis T, et al. Collection, tumor contamination, and engrafrment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood. 1998;91:4489-4495.
40. Michallet M, Archimbaud E, Philip I, et al. Transplantation with selected autologous peripheral blood CD34+Thy-1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of the HSC dose on engraftment, safety and immune reconstitution. Unpublished manuscript.
41. Shpall EJ, Wheeler CA, Turner SA, et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood. 1999;93:2491-2501.
42. Bomberger C, Singh-Jairam M, Rodey G, et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood. 1998; 91:2588-2600.
43. Franklin WA, Glaspy J, Pflaumer SM, et al. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. Blood. 1999;94:340-347.
44. Franklin WA, Shpall EJ, Archer P, et al. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat. 1996;41:1-13.
45. Passos-Coelho JL, Ross AA, Kahn DJ, et al. Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol. 1996;14:2569-2575.